Navigation Links
Spectrum Pharmaceuticals and Cell Therapeutics to Jointly Market ZEVALIN, a Proprietary, Marketed Oncology Drug
Date:11/26/2008

fective in treating indolent NHL. Although approved by the FDA in 2002, its potential has not been fully realized. We are proud to partner with Cell Therapeutics, which over the past year has made great headway toward removing many of the obstacles that have kept this important drug from patients that could benefit from it. There are approximately one thousand patients currently receiving ZEVALIN treatments for refractory indolent NHL, generating approximately $15 million in annual sales. If approved for first line consolidation therapy in indolent NHL, we estimate that an additional 18,000 patients per year would be eligible to receive ZEVALIN in this setting. We assembled an experienced sales force, comprised of individuals with established track records of success, to launch our recently approved drug FUSILEV. ZEVALIN represents a complementary product that our sales force can provide to their accounts."

"This partnership is especially important as we hope to move toward use of ZEVALIN in first-line consolidation treatment of indolent NHL patients, which would significantly expand the available patient population," said James A. Bianco, M.D., CEO of Cell Therapeutics. "This partnership will enable CTI to deploy a larger combined sales and marketing team to accelerate top-line product revenues in the near-term and reduce our costs to develop ZEVALIN for new growth opportunities, resulting in an increase in CTI's bottom-line overall. Spectrum has a wealth of experience in the field of oncology, including the sales and marketing leadership that oversaw the successful launch of Abraxane(R) and Xeloda(R). We believe the Spectrum partnership allows us to better serve patients and capitalize on the growing recognition of ZEVALIN's effectiveness in patients with indolent NHL, while at the same time provide a significant return on investment for our shareholders."

Under terms of the agreement, upon the closing o
'/>"/>

SOURCE Spectrum Pharmaceuticals, Inc.; Cell Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. GEECF: Spectrum Launches Zero Waste Philippines and Gears Towards Cheap Green Energy
2. Geecf: Spectrum Blue Steel Announces Strategic Partnership with Al Manhal International Group of Abu Dhabi to Deploy Biosphere Facilities
3. "Brave New Reality" Provides a Wide Spectrum of High Tech News and Easy Science.
4. Spectrum Blue Steel's fresh foreign investment at 18 Billion and the Biosphere process spark attention on a global scale
5. Energetiqs Laser-Driven Light Source Technology Enables Continuous Spectrum Light Sources, from Visible to Deep Ultraviolet
6. AEterna Zentaris Partner, Spectrum, Provides Update on Ozarelix in Benign Prostatic Hyperplasia
7. FDA Accepts ISO-Vorin(TM) New Drug Application Amendment Submitted by Spectrum Pharmaceuticals
8. Spectrum Pharmaceuticals Initiates Second Registrational Phase 3 Clinical Trial for EOquin(R) in Patients With Non-Invasive Bladder Cancer
9. Global Experts Explore Entire Spectrum of Aids Vaccine Development
10. Cephalon and Eurand File Patent Infringement Lawsuit Against Mylan Pharmaceuticals and Barr Pharmaceuticals
11. Anadys Pharmaceuticals to Present at the Piper Jaffray Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... 27, 2015 Working in collaboration with ... London , Richmond Pharmacology is the first ... 3 study for an investigational RNAi therapeutic being developed for ... the nerves and heart. Read press release ... Based at St Georges University of London ...
(Date:3/26/2015)... 2015 PRC Clinical, a Silicon-Valley based ... management and executive appointments effective immediately. , Mike Catelani ... and member of the Board of Directors. Daniel Head ... Sue Dowden will assume the position of Senior Director ... Operations Officer (COO), has been appointed to the position ...
(Date:3/26/2015)... 2015 Neogen Corporation (NASDAQ: NEOG ) ... quarter of fiscal 2015, which ended Feb. 28, increased ... $6,575,000. Earnings per share in the current quarter were ... net income increased 17% over prior year to $24,142,000, ... per share, for the same period a year ago. ...
(Date:3/26/2015)... 26, 2015 WriteResult, a premier provider ... from Yale University’s School of Public Health and New ... during a 4 month-long project. The goal of the ... income families with free access to fresh produce and ... health concerns like high blood pressure, diabetes and weight ...
Breaking Biology Technology:PRC Clinical Announces Key Management Appointments and Launches East Coast Operations 2PRC Clinical Announces Key Management Appointments and Launches East Coast Operations 3Neogen reports 13% increase in net income 2Neogen reports 13% increase in net income 3Neogen reports 13% increase in net income 4Neogen reports 13% increase in net income 5Neogen reports 13% increase in net income 6Neogen reports 13% increase in net income 7Neogen reports 13% increase in net income 8Yale and New Haven Farms Improving Patient Health with WriteResult's myPROpad™ 2Yale and New Haven Farms Improving Patient Health with WriteResult's myPROpad™ 3
... RICHMOND, Calif., Sept. 8 /PRNewswire-FirstCall/ -- Scientists ... by Sangamo BioSciences, Inc., (Nasdaq: SGMO ) to ... cells (hESCs) and induced pluripotent stem cells (hiPSCs). Human ESCs ... Scientists also hope to use these cells therapeutically in ...
... , CRANBURY, N.J., Sept. 8, Palatin Technologies, ... its fourth quarter and fiscal year ended June 30, 2009. ... million, compared to $11.5 million for year ended June 30, 2008. ... was $4.8 million, or $(0.06) per basic and diluted share, compared ...
... ... which is also ranked as one of Britain’s most respected companies, has singled out ... , ... 8, 2009 -- Thomson Reuters, one of the world’s largest stock market analytics firms ...
Cached Biology Technology:Sangamo's Zinc Finger Nuclease Technology Used to Efficiently Modify Human Stem Cells 2Sangamo's Zinc Finger Nuclease Technology Used to Efficiently Modify Human Stem Cells 3Sangamo's Zinc Finger Nuclease Technology Used to Efficiently Modify Human Stem Cells 4Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2009 Results; Teleconference and Webcast to be held on September 8, 2009 2Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2009 Results; Teleconference and Webcast to be held on September 8, 2009 3Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2009 Results; Teleconference and Webcast to be held on September 8, 2009 4Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2009 Results; Teleconference and Webcast to be held on September 8, 2009 5Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2009 Results; Teleconference and Webcast to be held on September 8, 2009 6Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2009 Results; Teleconference and Webcast to be held on September 8, 2009 7Reuters Highlights NutraPharma Financial Giant Predicts NutraPharma (OTCBB: NPHC) Shares Likely to Outperform the Market 2
(Date:3/20/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/rswjb4/hand_geometry ) ... Global Strategic Business Report" report to their offering. ... in US$ Thousands. The report provides separate comprehensive analytics for ... , Europe , Asia-Pacific ... of World. Annual estimates and forecasts are provided ...
(Date:3/19/2015)... Conn. , March 19, 2015  NXT-ID, Inc. (NASDAQ: ... authentication company focused on the growing mobile commerce market, announces ... in a news clip that aired this week on ... ) . In a segment "The Next Great ... wallet ,a new way to pay, and ,a really big ...
(Date:3/17/2015)... 2015 Emotient, the leader in facial ... general availability of Emotient Analytics , the ... of facial expressions. The system analyzes videos of ... and services. It delivers audience response metrics - ... as derived from facial evidence of emotional states. ...
Breaking Biology News(10 mins):Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 2Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 3Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 4NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 2NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 3New Emotient Web Service Measures Audience Response Using On-Demand Facial Expression Analysis 2New Emotient Web Service Measures Audience Response Using On-Demand Facial Expression Analysis 3New Emotient Web Service Measures Audience Response Using On-Demand Facial Expression Analysis 4
... SACRAMENTO, Calif. -- The University of California, Davis, and ... have signed a historic agreement that will change the ... states, and foster critical breakthroughs in the areas of ... new partnership will establish a state-of-the-art BGI sequencing facility ...
... In an experiment on rats, European researchers have proved ... cause to the stomach mucous membrane. Published in the ... to improving the treatment of stomach ulcers. A ... the protecting effect that strawberries have in a mammal ...
... era of environmental consciousness, many buildings are being outfitted to ... literally. Elizabeth Demaray, an associate professor of fine arts, ... skyscrapers to counteract the lack of native vegetation found in ... part of New York,s Art in Odd Places Festival from ...
Cached Biology News:UC Davis and BGI announce partnership to establish state-of-the-art genome center in Sacramento 2UC Davis and BGI announce partnership to establish state-of-the-art genome center in Sacramento 3Strawberries protect the stomach from alcohol 2Rutgers professor uses lichen to help cities go green 2Rutgers professor uses lichen to help cities go green 3
Prostaglandin E2 Luminex Standard Product Lines: Unspecified...
Agarose-ME, 500 g. Suitable for immunoelectrophoresis.Gel point (1.5%): 36 1.5 C, EEO (-mr): 0.16-0.19, Gel strength (1%): > 1000 g/cm2. Category: Nucleotides & Enzymes & Biochemicals, Ultrapure Bio...
ERalpha (Ser 104/106)...
... Phosphatase, Calf Intestinal (CIAP), catalyzes the hydrolysis ... ribo- and deoxyribonucleoside triphosphates. This enzyme is ... linearized cloning vector DNA by removing phosphate ... be used for the dephosphorylation of 5 ...
Biology Products: